Arisaph Pharmaceuticals

Arisaph Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for cancer, cardiovascular disease, and diabetes. Its products include dipeptidylpeptidase IV inhibitors, stable GLP-1 agonists, HDL modulators and plaque reducers, and tumor activated pro-soft drugs. The company was founded in 1999 and is based in Boston, Massachusetts.